

NYRx the Medicaid Pharmacy Program

PDE-5 Inhibitors for Pulmonary Arterial Hypertension (PAH) Prior Authorization Worksheet

Fax Number: 1-800-268-2990

Processing may be delayed if information submitted is illegible or incomplete. If your fax includes the standardized fax form, only the **Enrollee Name**, **Date of Birth**, **Medicaid ID**, and **Clinical Criteria** need to be completed and faxed as an attachment to process your request. For diagnoses other than PAH, please call the Clinical Support Center at 1-877-309-9493 to request a prior authorization.

ENROLLEE INFORMATION	
Enrollee's Last Name:	Enrollee's First Name:
Date of Birth:	Enrollee's Medicaid ID (2 letters, 5 numbers, 1 letter):
PRESCRIBER INFORMATION	
Prescriber's Last Name:	Prescriber's First Name:
National Provider Identifier (NPI) Number	Board Certified Specialty:
Prescriber's Street Address:	
City:	State: Zip Code
Prescriber's Phone Number:	Prescriber's Fax Number:
REQUESTED PREFERRED DRUG INFORM	/IATION
Drug Name (sildenafil OR tadalafil):	
sildenafil (generic for Revatio®)	
☐ tadalafil (generic for Adcirca®)	
Drug Strength:	Quantity: Refills:
Directions:	
New Prescription: Yes No	If NO , date therapy was initiated:

En	nrollee's Last Name:	Enrollee's Fi	rst Name:		
REQUESTED NON-PREFERRED DRUG INFORMATION					
Dr	rug Name:				
Dr	rug Strength:	Quantity:	Refills:		
Di	rections:				
Ne	ew Prescription: Yes N	lo If NO , date therapy was	s initiated:		
CL	INICAL CRITERIA				
1.	The Food and Drug Administration dose requested is higher, what is	` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	s 20 mg TID for Revatio®/sildenafil. If the ng the dose?		
2.	What is the diagnosis documente type 5 (PDE-5) inhibitor?	ed in the patient's chart that red	quires treatment with a phosphodiesterase		
3.	•		r disease, or is there documentation in the ertified in pulmonary or cardiovascular		
QI	UESTIONS 4–9 ARE FOR INITIAL	REQUESTS ONLY			
	ease provide all the following valu ocumentation is required for initia	_	zation (Questions 4–8). Supporting		
4.	If a right heart catheterization w explains why the patient was una		entation supports the diagnosis and theterization?		
5.	What is the mean pulmonary art required:	ery pressure (either at rest or w	rith exercise)? – Supporting documentation		
6.	What is the pulmonary artery oc	clusion pressure (wedge pressu	re)? – Supporting documentation required		
7.	If the wedge pressure is > 15 mm documentation required:	nHg, what is the clinical explana	tion for high wedge pressure? – Supporting		

EN	rollee's Last Name:
CL	INICAL CRITERIA (CONTINUED)
8.	What is the acute pulmonary vasoreactivity (as determined during right catheterization)? – Supporting documentation required:
	Positive responder
	Negative responder
	Not tested – Please provide an explanation for not performing this test and indicate if the patient has failed on a calcium channel blocker:
9.	What New York Heart Association/World Health Organization (NYHA/WHO) classification describes the
	patient's current functional status?
10	. Before prescribing this drug, have you inquired about regular or intermittent therapy with nitrates or drug containing nitrates within the past 180 days and completed counseling of this patient, including strong warning against the use of any drugs containing nitrates in conjunction with a PDE-5 inhibitor? Yes No
11	. Is this patient currently using an oral erectile dysfunction medication? Yes No
ava kno	omission of this form confirms the information is accurate and true, and that the supporting documentation is allable for review upon request of said plan, the NYSDOH or CMS. The submitter understands that any person who owingly makes or causes to be made a false record to statement that is material to a Medicaid claim may be subject civil penalties and treble damages under both federal and NYS False Claims Acts.
Fa	x Number: 1-800-268-2990
Pri	or Authorization Call Line: 1-877-309-9493
	l

Billing Questions: 1-800-343-9000

For clinical questions or Clinical Drug Review Program questions, please visit http://newyork.fhsc.com or call 1-877-309-9493.